The right-wing argues, as Project 2025 puts it, that government negotiations on Medicare drugs amount to “price controls” that will reduce patient access to new medication. That’s news to the citizens ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...

A couple of months ago, healthcare equity research analyst Jared Holz from Mizuho spoke about Viking potentially being an acquisition target. During his discussion, Holz suggested that Viking could ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Major stock indexes closed higher/lower on Friday, after the week saw a flurry of events including DeepSeek scare and ...

President Donald Trump said his administration will install 25% tariffs on goods from Canada and Mexico, ending the largely ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported ...

While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug ...

It’s a problem that has plagued European governments for decades, from the credit-crunch bank bailouts of 2008 to more recent ...

Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals that distract from plans that would hit Americans -- like drug prices.

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...